JP2015518001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518001A5 JP2015518001A5 JP2015505958A JP2015505958A JP2015518001A5 JP 2015518001 A5 JP2015518001 A5 JP 2015518001A5 JP 2015505958 A JP2015505958 A JP 2015505958A JP 2015505958 A JP2015505958 A JP 2015505958A JP 2015518001 A5 JP2015518001 A5 JP 2015518001A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- substitution
- acid position
- type residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624194P | 2012-04-13 | 2012-04-13 | |
| US61/624,194 | 2012-04-13 | ||
| US201361785169P | 2013-03-14 | 2013-03-14 | |
| US61/785,169 | 2013-03-14 | ||
| PCT/US2013/036452 WO2013155464A1 (en) | 2012-04-13 | 2013-04-12 | Combination therapy for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141119A Division JP2017190337A (ja) | 2012-04-13 | 2017-07-20 | がんを処置するための組合せ治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518001A JP2015518001A (ja) | 2015-06-25 |
| JP2015518001A5 true JP2015518001A5 (https=) | 2016-06-09 |
| JP6340361B2 JP6340361B2 (ja) | 2018-06-06 |
Family
ID=49328220
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505958A Active JP6340361B2 (ja) | 2012-04-13 | 2013-04-12 | がんを処置するための組合せ治療 |
| JP2017141119A Withdrawn JP2017190337A (ja) | 2012-04-13 | 2017-07-20 | がんを処置するための組合せ治療 |
| JP2019134563A Withdrawn JP2019196386A (ja) | 2012-04-13 | 2019-07-22 | がんを処置するための組合せ治療 |
| JP2021079088A Withdrawn JP2021119191A (ja) | 2012-04-13 | 2021-05-07 | がんを処置するための組合せ治療 |
| JP2023072566A Active JP7759910B2 (ja) | 2012-04-13 | 2023-04-26 | がんを処置するための組合せ治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141119A Withdrawn JP2017190337A (ja) | 2012-04-13 | 2017-07-20 | がんを処置するための組合せ治療 |
| JP2019134563A Withdrawn JP2019196386A (ja) | 2012-04-13 | 2019-07-22 | がんを処置するための組合せ治療 |
| JP2021079088A Withdrawn JP2021119191A (ja) | 2012-04-13 | 2021-05-07 | がんを処置するための組合せ治療 |
| JP2023072566A Active JP7759910B2 (ja) | 2012-04-13 | 2023-04-26 | がんを処置するための組合せ治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10301290B2 (https=) |
| EP (2) | EP4140487A1 (https=) |
| JP (5) | JP6340361B2 (https=) |
| KR (5) | KR102747818B1 (https=) |
| CN (2) | CN104768555B (https=) |
| AU (3) | AU2013245661B2 (https=) |
| BR (1) | BR112014025506B1 (https=) |
| CA (1) | CA2870010C (https=) |
| ES (1) | ES2925312T3 (https=) |
| IL (6) | IL319364A (https=) |
| MX (2) | MX367793B (https=) |
| NZ (2) | NZ700759A (https=) |
| RU (1) | RU2699546C2 (https=) |
| SG (3) | SG10201912111TA (https=) |
| WO (1) | WO2013155464A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SG10201912111TA (en) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Combination therapy for treating cancer |
| PT3184523T (pt) | 2012-04-13 | 2019-09-26 | Eisai R&D Man Co Ltd | Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico |
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| MX2015004721A (es) | 2012-10-15 | 2016-01-25 | Epizyme Inc | Compuestos de benceno sustituidos. |
| EP2931707A4 (en) | 2012-12-13 | 2016-07-20 | Glaxosmithkline Llc | AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS |
| KR20150127216A (ko) * | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20160030221A (ko) | 2013-07-10 | 2016-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| MA38949A1 (fr) | 2013-10-16 | 2017-07-31 | Eisai R&D Man Co Ltd | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
| WO2015058125A1 (en) * | 2013-10-18 | 2015-04-23 | Epizyme, Inc. | Method of treating cancer |
| CN116019921A (zh) * | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| BR112016029492A2 (pt) | 2014-06-17 | 2017-10-17 | Eisai R&D Man Co Ltd | método para tratamento de linfoma não hodgkin |
| EA201790845A1 (ru) * | 2014-10-16 | 2017-08-31 | Эпизайм, Инк. | Способ лечения рака |
| EP3885343A1 (en) | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Indole compounds as ezh2 inhibitors and uses thereof |
| HUE062159T2 (hu) | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| WO2016172199A1 (en) * | 2015-04-20 | 2016-10-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| CN105017404A (zh) * | 2015-07-20 | 2015-11-04 | 吉林省吉诺生物工程有限责任公司 | 一种检测肝癌标志物ezh2抗原表位氨基酸序列及应用 |
| WO2017019721A2 (en) * | 2015-07-28 | 2017-02-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| CA2999898A1 (en) * | 2015-09-25 | 2017-03-30 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor |
| EP3407978A4 (en) * | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| PL3423061T3 (pl) | 2016-03-02 | 2024-12-16 | Medivir Aktiebolag | Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny |
| AU2017252460B2 (en) | 2016-04-22 | 2021-11-18 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
| US10987353B2 (en) * | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2017218953A1 (en) | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Ezh2 inhibitors for treating cancer |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CN108314677B (zh) * | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| US20190350929A1 (en) * | 2017-02-02 | 2019-11-21 | Epizyme, Inc. | Cancer treatment modalities |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN111093660A (zh) * | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| WO2020112868A1 (en) * | 2018-11-30 | 2020-06-04 | Aileron Therapeutics, Inc. | Combination therapy of peptidomimetic macrocycles |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| CN113631541B (zh) * | 2019-03-25 | 2024-10-01 | 上海华汇拓医药科技有限公司 | 酰胺类化合物制备方法及其在医药领域的应用 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| US12252493B2 (en) | 2019-06-05 | 2025-03-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| WO2021016414A1 (en) | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| WO2021016409A1 (en) * | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| CN113024516B (zh) * | 2021-03-29 | 2022-05-17 | 中国药科大学 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
| CN113248481B (zh) * | 2021-04-19 | 2023-03-24 | 中山大学 | Ezh2共价不可逆抑制剂、制备方法及其用途 |
| CN113506296B (zh) * | 2021-09-10 | 2021-12-28 | 之江实验室 | 一种基于先验知识ct亚区影像组学的慢阻肺诊断装置 |
| CN116655612A (zh) * | 2023-05-09 | 2023-08-29 | 王亚男 | 一种ezh2抑制剂的合成方法及应用 |
| CN120624647B (zh) * | 2025-05-30 | 2026-04-03 | 山西省肿瘤医院 | 鼻咽癌诊断或预测的甲基化标志物组合及应用、试剂盒和计算机可读存储介质 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IL158574A0 (en) * | 2001-05-24 | 2004-05-12 | Leo Pharma As | Novel pyridyl cyanoguanidine compounds |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| WO2004069249A1 (en) * | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
| CA2517256C (en) | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| JP2005015422A (ja) * | 2003-06-27 | 2005-01-20 | Japan Tobacco Inc | 非即時型アレルギー疾患治療剤 |
| CN1286973C (zh) * | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
| WO2007114896A2 (en) * | 2006-03-31 | 2007-10-11 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
| ATE533489T1 (de) * | 2006-11-27 | 2011-12-15 | Ares Trading Sa | Behandlung von multiplem myelom |
| WO2010034006A2 (en) * | 2008-09-22 | 2010-03-25 | University Of Southern California | The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2. |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| ES2951688T3 (es) | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP3536314A1 (en) * | 2012-03-12 | 2019-09-11 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| SG10201912111TA (en) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Combination therapy for treating cancer |
| PT3184523T (pt) | 2012-04-13 | 2019-09-26 | Eisai R&D Man Co Ltd | Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2016172199A1 (en) * | 2015-04-20 | 2016-10-27 | Epizyme, Inc. | Combination therapy for treating cancer |
-
2013
- 2013-04-12 SG SG10201912111TA patent/SG10201912111TA/en unknown
- 2013-04-12 KR KR1020227042627A patent/KR102747818B1/ko active Active
- 2013-04-12 IL IL319364A patent/IL319364A/en unknown
- 2013-04-12 IL IL308807A patent/IL308807B2/en unknown
- 2013-04-12 CA CA2870010A patent/CA2870010C/en active Active
- 2013-04-12 US US14/394,463 patent/US10301290B2/en active Active
- 2013-04-12 BR BR112014025506-7A patent/BR112014025506B1/pt active IP Right Grant
- 2013-04-12 SG SG11201406440TA patent/SG11201406440TA/en unknown
- 2013-04-12 KR KR1020147031741A patent/KR102117982B1/ko active Active
- 2013-04-12 EP EP22177404.5A patent/EP4140487A1/en active Pending
- 2013-04-12 WO PCT/US2013/036452 patent/WO2013155464A1/en not_active Ceased
- 2013-04-12 KR KR1020217037101A patent/KR102475758B1/ko active Active
- 2013-04-12 KR KR1020247042572A patent/KR20250007688A/ko active Pending
- 2013-04-12 AU AU2013245661A patent/AU2013245661B2/en active Active
- 2013-04-12 JP JP2015505958A patent/JP6340361B2/ja active Active
- 2013-04-12 ES ES13776380T patent/ES2925312T3/es active Active
- 2013-04-12 CN CN201380030860.3A patent/CN104768555B/zh active Active
- 2013-04-12 IL IL289300A patent/IL289300B2/en unknown
- 2013-04-12 NZ NZ700759A patent/NZ700759A/en unknown
- 2013-04-12 SG SG10201608579UA patent/SG10201608579UA/en unknown
- 2013-04-12 MX MX2014012381A patent/MX367793B/es active IP Right Grant
- 2013-04-12 RU RU2014145552A patent/RU2699546C2/ru active
- 2013-04-12 EP EP13776380.1A patent/EP2836216B1/en active Active
- 2013-04-12 CN CN201811149973.6A patent/CN109745316B/zh active Active
- 2013-04-12 MX MX2019010601A patent/MX392752B/es unknown
- 2013-04-12 KR KR1020207015118A patent/KR20200062386A/ko not_active Ceased
- 2013-04-12 NZ NZ729643A patent/NZ729643A/en unknown
-
2014
- 2014-10-05 IL IL234989A patent/IL234989B/en active IP Right Grant
-
2017
- 2017-07-20 JP JP2017141119A patent/JP2017190337A/ja not_active Withdrawn
- 2017-11-02 AU AU2017254925A patent/AU2017254925A1/en not_active Abandoned
-
2018
- 2018-04-08 IL IL258544A patent/IL258544B/en active IP Right Grant
-
2019
- 2019-04-02 US US16/372,657 patent/US10787440B2/en active Active
- 2019-05-14 AU AU2019203351A patent/AU2019203351B2/en active Active
- 2019-07-22 JP JP2019134563A patent/JP2019196386A/ja not_active Withdrawn
-
2020
- 2020-01-23 IL IL272206A patent/IL272206B/en unknown
- 2020-08-05 US US16/985,404 patent/US11370781B2/en active Active
-
2021
- 2021-05-07 JP JP2021079088A patent/JP2021119191A/ja not_active Withdrawn
-
2022
- 2022-05-23 US US17/751,153 patent/US20220281854A1/en not_active Abandoned
-
2023
- 2023-04-26 JP JP2023072566A patent/JP7759910B2/ja active Active
-
2024
- 2024-06-05 US US18/734,942 patent/US20250109123A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518001A5 (https=) | ||
| RU2014145552A (ru) | Комбинированная терапия для лечения рака | |
| JP2016515561A5 (https=) | ||
| CR20200149A (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| MY207716A (en) | Hiv inhibitor compounds | |
| JP2015537020A5 (https=) | ||
| JP2019521988A5 (https=) | ||
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2017528524A5 (https=) | ||
| JP2015143283A5 (https=) | ||
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| CA2472372A1 (en) | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | |
| JP2016531126A5 (https=) | ||
| BR112022007488A2 (pt) | Forma cristalina de base livre de um receptor c5a de componente do complemento | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| PH12017501687A1 (en) | Inhibitors of hepatitis c virus polymerase | |
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| PH12021550878A1 (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| WO2020232191A8 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| JP2018502100A5 (https=) |